1. In Vivo

Celltech Gets Second Bite of CDP 870 Cherry

 
• By Hazel Dawson

When Big Pharma companies hand back licensed products to their biotech originators it's generally considered bad news for the biotech. But it needn't always be so. Pfizer's decision to return rights to Celltech's anti-inflammatory antibody CDP 870 hit Celltech's share price hard, but could ultimately open up a wealth of options and opportunities to the company.

In mid-November, Pfizer Inc. unpleasantly surprised UCB Celltech 's investors by putting the CDP 870 Phase III rheumatoid arthritis (RA) program on hold. That it wanted to renegotiate the terms of the licensing agreement came completely out of the blue and led to a 20% dive in Celltech's share price. Few were surprised however, when just two weeks later, having failed to convince Celltech to accept new, altogether less favorable terms, Pfizer announced it would hand back all rights to the compound.

When a Big Pharma hands back a licensed product to its biotech partner, for other than anti-trust reasons, it's generally...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.